Business Wire

FTRACK

20.4.2022 18:32:06 CEST | Business Wire | Press release

Share
ftrack reimagines ftrack Review and launches cineSync 5, the next generation of media review

ftrack , the developer of Academy Award-winning media review and team collaboration solutions for the creative industries, has launched significant updates to two of its flagship offerings: ftrack Review , the browser-based platform for interactive media review, and cineSync , the desktop media review solution heavily utilized by the film and television industries. ftrack Review’s new free-flowing user experience makes for a more lightweight, accessible media review experience for creatives, while cineSync’s fundamental update addresses the evolving needs of VFX studios working today.

Both ftrack Review’s reimagined workflows and cineSync 5 are available to try today. cineSync 5 is available as a free extension for all cineSync 4 Pro users.

ftrack was recently acquired by Backlight, a media technology company serving media, entertainment and video-forward customers with technology solutions that dramatically improve every step of the media content lifecycle. The acquisition allows ftrack to focus on product development and innovation, and provide its customers with the best possible tools and solutions like ftrack Review and cineSync.

ftrack Review Reimagined

ftrack Review introduces a newly updated, modern user interface designed for highly intuitive, user-friendly review sessions, alongside a greater focus on efficiency.

“We’ve listened to our customers’ feedback and have incorporated it into a new ftrack Review update that makes for a more responsive media review experience,” says Rory McGregor, product manager. “Users can now benefit from everything they enjoyed before—including centralized feedback cycles and interactive real-time review—but with the added advantage of a much more effortless workflow. We’re excited to see what our users think as we advance our multifaceted media review ecosystem at ftrack.”

Some of the new features in ftrack Review include:

  • An all-new interface designed to make reviews more free-flowing
  • Faster, more streamlined and responsive reviews with fewer clicks, even when reviewing larger projects with lots of guests and notes
  • A newly designed feedback bar
  • New toolbar features like ghosting, flip and flop, and resolution selection
  • New features for the power user, including tools to manage reviews from within the player interface.

See the complete list of features in ftrack Review’s latest update

ftrack Review's new features are planned to be implemented into ftrack Studio soon—ftrack's full production tracking, shot management, and media review platform

"The latest update to ftrack Review shows that ftrack has listened to our needs and quickly implemented much-valued new features,” says John Valentine, ftrack/workflow coordinator at Blue Zoo Animation Studio, an animation studio known for producing children's television series, advertising commercials, and short films. “With a new, user-friendly UI, an intuitive design layout, and more emphasis on what's being reviewed, it has never been easier for ourselves or our clients to view, comment and review material, we at Blue Zoo are excited by what we've seen and what's coming next."

Introducing cineSync 5

cineSync 5 is built on the legacy of industry-leading cineSync, now reimagined and rebuilt from the ground up to meet the evolving demands of creative review and approval. cineSync 5 streamlines the media review process and supports more collaborative reviews—both local and remote—while still meeting the highest requirements across security and performance that cineSync users have come to expect over the last 17 years.

Some of the new features in cineSync 5 include:

  • A new infrastructure designed to support faster, more responsive reviews
  • Local review without a license via cineSync Play
  • OTIO and OCIO v2 support
  • Frame/image sequence playback and OpenEXR support
  • Enhanced production tracking integrations with ftrack Studio and ShotGrid
  • Localization support
  • A new, modern UI

See the complete list of features in cineSync 5

“We’re excited to share cineSync 5 with our cineSync Pro users so they can get a first taste of the future of cineSync,” says Rory McGregor, product manager. “We’ve improved performance, added new features and workflows, updated our sync servers, and redesigned the UI. With these new features, we’re ushering in a new generation for cineSync—one that will make our users’ collaborative workflows more productive than ever before.”

“cineSync 5 is a significant upgrade on an application that's already the best in class. The killer news was the totally overhauled comparison tool with single-key access to shots, interactive and customizable wipe-line, and 0-100% cross-fades,” said Jake Morrison, VFX supervisor, Thor Love & Thunder . “Bonus points for being able to drag anywhere in the window to scrub back and forth with just a hotkey. I never knew I needed it, but now I use it all the time! Congrats to the cineSync team for an outstanding update to an already indispensable tool. They've clearly listened to their users – every new feature feels like it adds functionality. Grab it!”

Ftrack will showcase cineSync5 and the new ftrack Review later this month at the NAB Show in Las Vegas from April 23 to April 27.

About ftrack

ftrack, a Backlight business, is the creator of ftrack Studio, cineSync, and ftrack Review, the Emmy and Academy Award-winning production tracking, interactive media review, and team collaboration platforms for the creative industries. ftrack’s solutions are designed for producers, supervisors, artists, and pipeline developers and make it easy to seamlessly and securely collaborate with anyone, anywhere. Both ftrack's products and company ethos are founded on the core belief that success results from great teamwork. ftrack has built a talented global team that works with honesty, flexibility, and inclusivity and seeks to build a future where process disappears behind progress. ftrack was founded in 2012 and acquired by Backlight in 2021. ftrack is celebrating its 10th anniversary in 2022. To learn how ftrack is helping creatives meet the ever-increasing demands of creative workflows, please visit ftrack.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye